© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. requirements is reported in Figure 1 . We have developed a new methodology to synthesize fluorogenic peptides that relies on a unique Fmoc-Trp(C 2 -BODIPY)-OH amino acid (1) 22 , which can be prepared by attaching a BODIPY fluorophore to the C 2 position of Trp via a spacer-free C-C linkage (Steps 1-35). Amino acid 1 mimics the molecular interactions of native Trp, and it possesses a fluorogenic label that can be used for live-cell imaging. Compound 1 shows high chemical stability, which we proved by conducting the test described in Steps 36 and 37 (a quality control test that can be implemented before using a stock of compound 1 that has been stored as described in PROCEDURE), excitation and emission spectra in the visible range and remarkable fluorescence enhancement in hydrophobic environments (i.e., when the peptide is binding to its target), which facilitates wash-free imaging experiments. We have validated the usefulness of 1 as a precursor of peptide-based imaging probes by derivatizing the antimicrobial peptide PAF26 (ref. 23), which shows high affinity and selectivity for fungal cells. In PROCEDURE section, we detail the synthesis of the fluorogenic analog of PAF26 (BODIPY-cPAF26) by conventional SPPS, simply using 1 instead of natural . We have also recently used amino acid 1 for the preparation of cyclic peptides as fluorescent reagents for imaging apoptotic bodies 24 . BODIPY-cPAF26 shows high resistance to proteolysis (which could be tested as described in Steps 90-94), strong fluorogenic response in hydrophobic environments (see also procedure reported in Steps 95-106) and no impairment of the activity and selectivity of the native peptide in human and fungal cells (see tests described in Steps 107-131 and 132-162, respectively). All these tests represent a comprehensive panel of characterization experiments that can be readily implemented in other peptide sequences modified with the fluorogenic amino acid 1. Finally, we describe the use of BODIPY-cPAF26 for fluorescence live-cell imaging of several fungal pathogens and real-time imaging of A. fumigatus , one of the most life-threatening human fungal pathogens. These imaging experiments should be considered as a template set of directions to be modified by readers in their experiments of choice, which may vary depending on the instrumentation (e.g., confocal microscope) and cell systems used.
IntroDuctIon
Peptides are excellent molecular frameworks for the generation of imaging agents because they bind with high affinity and specificity to their targets. However, most peptides cannot be directly visualized using fluorescence imaging, as they lack proper reporter groups and need to be modified with fluorophores or reactive tags for further derivatization 1 . A milestone in peptide and protein labeling has been the development of genetically encoded unnatural amino acids, which can be incorporated in response to nonsense or frameshift codons to embed suitable bioorthogonal groups at specific sites of peptides and proteins 2 . Recent advances that have driven a progress in the field of fluorescence imaging include the genetic encoding of norbornene amino acids, which can rapidly and specifically couple to tetrazinecontaining fluorophores for protein labeling 3 , and the optimization of orthogonal variants of the inverse-electron-demand Diels-Alder cycloaddition reaction for dual-color live-cell imaging and super-resolution microscopy 4, 5 .
In addition to synthetic biology strategies, many unnatural amino acids are available as building blocks to expand the chemical diversity within peptide sequences using solid-phase peptide synthesis (SPPS) 6, 7 . These building blocks include unnatural amino acids with chemical groups amenable to two-step labeling processes (e.g., azides, alkynes and alkenes). Once peptides containing these amino acids are synthesized, they are coupled to a suitable fluorophore (using, e.g., 'click' chemistry), and the excess labeling agent is washed out before image acquisition. This approach has proven useful for many different applications [8] [9] [10] [11] , although the need for washing steps might hamper its implementation in in vivo and real-time imaging. Recent progress has involved the preparation of the bioorthogonal fluorophores with bright fluorescence emissions after the conjugation reaction, which leads to a reduction in fluorescence background and a minimization of the washing steps [12] [13] [14] . Moreover, further development of synthetic methodologies to diversify amino acids and peptides [15] [16] [17] will create opportunities for direct fluorescence labeling and in situ imaging studies.
Most commonly, peptides are readily labeled by attaching a fluorophore to a residue in the peptide sequence, yielding fluorescent conjugates that can be directly used for imaging. However, fluorophores have bulky structures that can impair the molecular recognition properties of the native peptide; it is, therefore, important to introduce fluorophores at appropriate positions within the amino acid sequence. Most of them are incorporated into peptides by reaction with terminal or side-chain chemical groups (e.g., amines, carboxylic acids and thiols) from polar residues or through chemical spacers [18] [19] [20] . As these modifications can disrupt the hydrogen bonding pattern with respect to the original peptide and have a detrimental effect on the biological properties of the fluorescent conjugate 21 , there is a demand for new technologies to incorporate fluorophores into peptides without affecting their inherent activity and, ideally, with suitable spectral properties for live-cell imaging applications.
Overview of the procedure A schematic flowchart outlining the different subsections of the PROCEDURE described in this protocol and their expected time requirements is reported in Figure 1 . We have developed a new methodology to synthesize fluorogenic peptides that relies on a unique Fmoc-Trp(C 2 -BODIPY)-OH amino acid (1) 22 , which can be prepared by attaching a BODIPY fluorophore to the C 2 position of Trp via a spacer-free C-C linkage (Steps 1-35). Amino acid 1 mimics the molecular interactions of native Trp, and it possesses a fluorogenic label that can be used for live-cell imaging. Compound 1 shows high chemical stability, which we proved by conducting the test described in Steps 36 and 37 (a quality control test that can be implemented before using a stock of compound 1 that has been stored as described in PROCEDURE), excitation and emission spectra in the visible range and remarkable fluorescence enhancement in hydrophobic environments (i.e., when the peptide is binding to its target), which facilitates wash-free imaging experiments. We have validated the usefulness of 1 as a precursor of peptide-based imaging probes by derivatizing the antimicrobial peptide PAF26 (ref. 23) , which shows high affinity and selectivity for fungal cells. In PROCEDURE section, we detail the synthesis of the fluorogenic analog of PAF26 (BODIPY-cPAF26) by conventional SPPS, simply using 1 instead of natural Trp (Steps 38-89). We have also recently used amino acid 1 for the preparation of cyclic peptides as fluorescent reagents for imaging apoptotic bodies 24 . BODIPY-cPAF26 shows high resistance to proteolysis (which could be tested as described in Steps 90-94), strong fluorogenic response in hydrophobic environments (see also procedure reported in Steps 95-106) and no impairment of the activity and selectivity of the native peptide in human and fungal cells (see tests described in Steps 107-131 and 132-162, respectively). All these tests represent a comprehensive panel of characterization experiments that can be readily implemented in other peptide sequences modified with the fluorogenic amino acid 1. Finally, we describe the use of BODIPY-cPAF26 for fluorescence live-cell imaging of several fungal pathogens (Steps 163-206) and real-time imaging of A. fumigatus (Steps 207-219), one of the most life-threatening human fungal pathogens. These imaging experiments should be considered as a template set of directions to be modified by readers in their experiments of choice, which may vary depending on the instrumentation (e.g., confocal microscope) and cell systems used.
Advantages and limitations of the protocol
A major advantage of this protocol is its general applicability, as it can be used to prepare fluorogenic analogs of most peptide sequences. Amino acid 1 is compatible with Fmoc-based SPPS protocols, tolerates standard deprotection and coupling conditions, as well as mild acid-based deprotection strategies, without any observable degradation of the BODIPY fluorophore 25, 26 . Notably, careful design of the protecting group scheme is needed to ensure full orthogonality with the BODIPY structure; for instance, in the synthesis of BODIPY-cPAF26, we used FmocLys(Z)-OH instead of Fmoc-Lys(Boc)-OH and Fmoc-Arg(NO 2 )-OH instead of Fmoc-Arg(Pbf)-OH to avoid any acid-sensitive protecting groups.
Importantly, the exact impact of Trp-BODIPY on the biomolecular properties of the labeled peptides should be examined on a case-by-case basis. Although most of the labeled bioactive peptides examined to date have shown activity patterns similar to those of their unlabeled, natural counterparts 22 , the introduction of Trp-BODIPY may prove detrimental to the activity of other peptides, and we recommend that researchers run proper tests (those described in Steps 132-162) to compare the functional properties of labeled and nonlabeled peptide sequences.
Regarding spectral properties, 1 has maximum wavelengths for both excitation and emission (λ exc. and λ em. , respectively) in the green region of the visible spectra (λ exc. ~500 nm, λ em. ~520 nm), which make it ideally suited for conventional GFP/FITC (fluorescein isothiocyanate) filters found in most spectrophotometers, flow cytometers, confocal microscopes and other imaging equipment. This characteristic is an important advantage with respect to naphthalene-, coumarin-and dansyl-based fluorescent amino acids that have been introduced as labels in peptides through SPPS [27] [28] [29] [30] . Once inserted into peptides, these fluorogenic groups display shorter excitation and emission wavelengths than 1, with relatively long Stokes shifts. Extensive work in this field has been performed by Imperiali and co-workers, who developed environmentally sensitive fluorescent amino acids as reporters of protein-protein interactions [31] [32] [33] [34] . These amino acids are mostly based on the naphthalimide scaffold and display remarkable fluorescence enhancements in hydrophobic environments, with excitation wavelengths ~400-450 nm and extinction coefficients ~10 3 to 10 4 M −1 cm −1 (refs. 35,36) . Although the emission enhancement of 1 in hydrophobic environments might be slightly lower than that of naphthalimide-based amino acids, its high extinction coefficient (i.e., around one order of magnitude higher than its counterparts) results in overall stronger brightness.
Unlike the case of peptides containing unnatural amino acids with reactive orthogonal groups, the strong fluorogenic behavior of 1 makes it possible for the relevant labeled peptides to be used directly for live-cell imaging in wash-free conditions, without any additional labeling steps. This feature represents a major advantage in imaging experiments in which dynamic processes in living cells are monitored in real time.
The main limitation of the present protocol is that it can be implemented only to label the peptides or small proteins that are currently accessible via semisynthetic approaches or through Fmoc-based SPPS.
Experimental design and critical parameters Fmoc-Trp(C 2 -BODIPY)-OH: chemical synthesis, fluorescence properties and shelf life. We designed the synthesis of 1 so as to obtain the Fmoc-protected compound, which can be readily used for the synthesis of medium-sized peptides by conventional SPPS. The BODIPY fluorophore was selected because of its compact structure and excellent spectral photophysical properties 37, 38 . We decided to incorporate it into the C 2 position of Trp in a spacerfree C-C linkage to maintain the main recognition features of the labeled peptides (e.g., charge balance, overall polarity and H-bond pattern). The retrosynthetic analysis of amino acid 1 involves the arylation of m-iodophenyl-BODIPY (3) on the unsubstituted C 2 position of Fmoc-Trp-OH (2) by Pd-catalyzed C-H activation [39] [40] [41] , using an approach we recently developed (Fig. 2) 16 . m-iodophenyl-BODIPY (3) can be prepared by acid-catalyzed condensation of m-iodobenzaldehyde (4) with two equivalents of 2,4-dimethylpyrrole (5), followed by 2,3-dichloro-5,6-dicyanop-benzoquinone oxidation and BF 3 complexation. Notably, all the starting materials needed for the synthesis of 1 (i.e., compounds 2, 4 and 5) are commercially available.
Following similar reported procedures 42 , compounds 4 and 5 are mixed in conditions of trifluoroacetic acid (TFA) catalysis to yield the expected adduct with loss of a water molecule after stirring at room temperature (RT; 20-25 °C) for 22 h in anhydrous dichloromethane. Notably, in our experience, the synthetic yields did not substantially improve in the presence of dehydrating agents such as 4Å molecular sieves. Next, 2,3-dichloro-5,6-dicyano-pbenzoquinone (DDQ) is added to the crude mixture with continuous stirring for 15 min, followed by the addition of an excess of triethylamine and BF 3 ·Et 2 O. The resulting dark green solution is stirred at RT for 4.5 h to produce compound 3 as the major product in a crude form. Liquid-liquid extraction followed by flash chromatography over silica gel affords compound 3 in an ~30% yield (over the three steps). Of note, we observed slightly lower synthetic yields when this reaction was scaled up to >200-mg scale. RT  4°C  -20°C  RT  4°C  -20°C  RT  4°C  -20°C  RT  4°C  -20°C   1 month  96%  96%   Solid  DCM  MeOH  DMF   96%  96%  98%  98%  98%  98%  98%  87%  97%  98%   2 months  96%  96%  96%  97%*  98%  98%  97%  98%  98%  55%  95%  98%   4 months  96%  96%  96%  97%*  97%*  98%  97%  98%  98%  3%  91%  98% 1. Next, the m-iodophenyl-BODIPY 3 is subjected to Pd-catalyzed arylation of Fmoc-Trp-OH (2) to afford the desired Fmoc-Trp(C 2 -BODIPY)-OH (1) (Fig. 3a) [43] [44] [45] . Amino acid 2, a slight excess of m-iodophenyl-BODIPY 3 (1.5 equiv.), AgBF 4 (1.0 equiv.), TFA (1.0 equiv.) as the acid source, and catalytic Pd(OAc) 2 (0.05 equiv.) are dissolved in N,N-dimethylformamide (DMF) and subjected to microwave irradiation for 20 min at 80 °C.
In our experience, 1 is isolated by normal-phase chromatography over silica gel in an ~70% yield. Although our attempts to scale up this reaction resulted in decreased yields, parallelization of the procedure is convenient and reproducible. Please note that conducting the reaction described above (Fig. 3a) under conventional heating requires higher temperatures and longer reaction times than those mentioned for microwave-based synthesis, and it leads to the formation of very complex crude mixtures because of the limited stability of the Fmoc and BODIPY groups in the mentioned conditions. These limitations make the preparation of 1 feasible only under microwave irradiation. Compound 1 displays maximum excitation and emission wavelengths in the green region of the visible spectrum (λ exc. : 503 nm, λ em. : 517 nm; Fig. 3b ). These spectral properties make it optimal for use in most spectrophotometers, flow cytometers and confocal microscopes, as these are generally equipped with excitation sources and emission filters matching the spectral properties of GFP or FITC (λ exc. ~ 490 nm, λ em. ~ 520 nm). Furthermore, we examined the chemical integrity of 1 in different conditions to determine the optimal storage conditions, as well as its shelf life ( Fig. 3c; Supplementary Figs. 1 and 2) . Amino acid 1 is completely stable when stored in the dark as a solid, even at RT, for up to 4 months (i.e., this was the longest time point measured at the time of submission). With respect to the common solvents used in peptide synthesis, we determined that 1 is fully stable in both dichloromethane and methanol solutions for up to 4 months, but loses the Fmoc group when it is stored in DMF for long periods of time at RT (13% degradation after 1 month, 45% after 2 months and 97% after 4 months), in agreement with previous reports on the stability of Fmoc-protected amino acids 46 . Moreover, even though we did not observe any degradation of the BODIPY core upon exposure to daylight, we recommend storing 1 and its derivatives in the dark as a precautionary measure. Altogether, these results confirm that 1 can be shipped and used as most Fmoc-protected amino acids, and can even be stored for several months in DMF at 4 °C or −20 °C.
Fluorogenic antimicrobial peptides: solid-phase synthesis, fluorogenic behavior and biological characterization. Given their selectivity for microbes over mammalian cells, fluorescent antimicrobial peptides are promising tools for imaging infectious pathogens 47, 48 . Our research group and others have studied the mechanism of action of Peptide AntiFungal 26 (PAF26), an antimicrobial hexapeptide with high affinity for fungal cells. PAF26 (H-RKKWFW-NH 2 ) has a short and conserved sequence with hydrophobic and cationic domains that are indispensable for its cellular activity 49 . We envisioned that fluorogenic PAF26 analogs, in which natural Trp is replaced by 1, would retain the activity and selectivity for fungal cells of the original sequence while incorporating a suitable label for fluorescence imaging. Furthermore, as cyclic peptides show increased resistance to proteases 50 (such as those secreted by infective pathogens), we designed the synthesis of a cyclic fluorogenic peptide (BODIPY-cPAF26, Figs. 4 and 5a) based on the sequence of PAF26. BODIPY-cPAF26 is synthesized using 2-chlorotrityl polystyrene resin and Fmoc-based SPPS protocols (Fig. 4) .
In the PROCEDURE, amino acid 1 and Fmoc-Gly-OH, FmocPhe-OH, Fmoc-Trp-OH, Fmoc-Lys(Z)-OH and Fmoc-Arg(NO 2 )-OH are used as fully mutually orthogonal building blocks in the mildly acidic cleavage conditions (TFA/dichloromethane (DCM) = 1:99) and enable the isolation of the fully protected cyclic peptide without damaging the BODIPY core. In the synthesis of BODIPY-cPAF26, all nonlabeled amino acids are incorporated at a concentration of 3 equiv., using conventional N,N′-diisopropylcarbodiimide (DIC) and OxymaPure, whereas 1 is incorporated using a moderate excess (1. We have compared the antimicrobial activity of PAF26 with that of BODIPY-cPAF26 and determined their IC 50 values for two different fungal species, Neurospora crassa and A. fumigatus. N. crassa is an experimental model organism for filamentous fungi 51 , whereas A. fumigatus is a fungal pathogen causing multiple human diseases, the most lethal of which is invasive pulmonary aspergillosis (IPA), an infection that causes ~200,000 deaths per year worldwide 52 . Notably, BODIPY-cPAF26 did not impair the antifungal activity of the original sequence, and it displayed slightly higher affinity for both fungal species than the unlabeled PAF26 peptide ( Fig. 5b;  Supplementary Table 1) . We also examined the fluorescence response of BODIPY-cPAF26 in phospholipid liposomes, which mimic the microenvironment of cell membranes. Fluorescence spectra of BODIPY-cPAF26 were recorded upon incubation with liposome suspensions of phosphatidylcholine/cholesterol (7:1) in phosphate buffered saline with increasing concentrations of phosphatidylcholine. As shown in Figure 5c , BODIPY-cPAF26 displayed strong fluorogenic behavior, with quantum yields slightly over 30% after binding to phospholipid membranes (Supplementary Table 2 ). Finally, we evaluated the cytotoxicity of BODIPY-cPAF26 in A549 lung epithelial cells as an indication of their poor affinity for human cells. We did not detect statistically significant differences (P > 0.05) in the viability of A549 cells with or without incubation of BODIPY-cPAF26 for several hours, even at relatively high concentrations (Fig. 5d) . Altogether, these results corroborate the suitability of the fluorogenic amino acid 1 as a Trp surrogate with minimal interference in the recognition properties of peptide sequences, which provides a suitable reporter for visualizing molecular interactions using fluorescence-based techniques.
As imaging infection sites using peptide-based probes can be hindered by the presence of proteolytic enzymes, we examined the chemical integrity of BODIPY-cPAF26 in proteolytic environments and compared its degradation with that of the unlabeled PAF26. The two peptides were incubated at the same concentration in a protease cocktail for >24 h, and time-course analysis was performed by HPLC-MS. Being a cyclic peptide, BODIPY-cPAF26 showed high stability to proteases, with marginal degradation after 24 h of incubation ( Supplementary Figs. 3 and 4) . In the same experimental conditions, the unlabeled linear peptide PAF26 was mostly degraded, with only 20% of intact peptide left after 24 h.
Live-cell fluorescence imaging of fungal pathogens, including
A. fumigatus. In view of the excellent properties of BODIPYcPAF26 as a highly stable and fluorogenic peptide for reporting of interactions with fungal cells, we used it for live-cell imaging of different fungal species. In addition to N. crassa and A. fumigatus, we also examined the staining of BODIPY-cPAF26 in other fungal pathogens, namely Cryptococcus neoformans, Fusarium oxysporum and Candida albicans. BODIPY-cPAF26 showed bright staining in all the species, suggesting a potential common target for different fungi (Fig. 6) . Notably, the fluorogenic behavior of BODIPY-cPAF26 enables live-cell imaging by simple incubation with the cells, in a single step and without the need for any washing protocols. This procedure represents an important advantage over imaging procedures with fluorescent peptides that are labeled using alternative procedures (e.g., 'click' fluorophores used in two-step labeling procedures or 'always-on' fluorophores that require washing).
As A. fumigatus is the fungal pathogen responsible for IPA, a life-threatening disease in immunocompromised patients 52 , we performed further studies to visualize the dynamic interaction between BODIPY-cPAF26 and living cells of A. fumigatus. Germlings of A. fumigatus were preincubated with a red fluorescent probe that first stained the whole plasma membrane and then intracellular vacuoles. Before the red membrane stain was internalized, we added BODIPY-cPAF26 to the cells and acquired time-course fluorescence images at high magnification to overlay the green signal from BODIPY-cPAF26 and the red signal from the counterstain ( Fig. 7; Supplementary Video 1) . 20 s after its addition, BODIPY-cPAF26 stained the plasma membrane in the apical region of the germling cells. In the following minutes, the green fluorescence signal moved toward the base of the germling, whereas the red counterstain started to accumulate in intracellular vacuolar organelles. These results validate our procedure using the amino acid Fmoc-Trp(C 2 -BODIPY)-OH as an efficient chemical strategy to prepare fluorogenic peptides for enhanced fluorescence live-cell imaging without any washing steps. As a proof-of-concept, we have synthesized BODIPY-cPAF26 as a stable, cyclic antimicrobial peptide for imaging dynamic processes in living fungal pathogens. ) and store at −20 °C. To avoid several freeze-thaw cycles, DMSO stocks should be ideally stored in small multiple aliquots, which can be kept at −20 °C for at least 6 months without any observed degradation. ! cautIon DMSO is highly toxic. Gloves must be worn at all times to avoid contact with skin. 1 mM Fluorescein in 0.1 N NaOH in EtOH Prepare a 10 mM solution of fluorescein in DMSO by weighing 3.3 mg and dissolving it in 1 ml of DMSO.
• 2 O to the flask, shake gently and, using a P1000 micropipette, transfer the suspension containing the fungal spores (conidia) to a 2-ml microcentrifuge tube. Add 0.5 ml of glycerol to the tube, shake gently and prepare stock suspension 100-µl aliquots in sterile 1.5-ml microcentrifuge tubes. If live-cell images are taken with a different microscope, excitation should be performed within the 450-to 500-nm (green) and the 550-to 600-nm ranges (red), and fluorescence emissions should be collected using either band-pass or long-pass filters covering the 500-to 550-nm (green) or 590-to 650-nm (red) ranges. Both water-and oil-immersion objectives can be used for image acquisition. The settings for image format and scanning speed should be adjusted depending on the requirements of the experiment. However, we recommend setting a high pixel format and slow scanning speeds whenever possible. 
Hplc-Ms (condition 1) Hplc-Ms (condition 2)
Column Phenomenex Gemini C18 110A reverse-phase column, 4.6 × 50 mm (particle size 3.5 µm)
XSelect CSH C18 reverse-phase column, 4.6 × 50 mm (particle size 3.5 µm) 
2|
Cap the flask with a rubber septum (30.7-mm diameter), place it on a magnetic stirrer and, using a 60-ml syringe under a N 2 stream, add 50 ml of anhydrous DCM to the flask while stirring the contents (stirring motion: 1,000 r.p.m.).
3|
Add 500 µl of 2,4-dimethylpyrrole (2.2 equiv., 4.7 mmol) to the flask with a 1-ml syringe under a N 2 stream with constant stirring.
4|
Using a 1-ml syringe, add four drops (~15 µl) of TFA to the flask under a N 2 stream. The solution should turn orange.  crItIcal step We recommend using a glass needle when working with TFA to avoid any potential contamination due to degradation of plastic syringes. 8| Weigh 490 mg of DDQ (1.0 equiv., 2.2 mmol) into a 50-ml conical flask and add to it 30 ml of anhydrous DCM.
5|
9| Shake and sonicate the resulting yellow suspension until it is almost completely dissolved.
10|
Using a syringe under a N 2 stream, add the solution prepared in Step 9 dropwise (for ~10 min) to the reaction mixture (stirring motion: 1,200 r.p.m.).
11|
Rinse the conical flask with 2 ml of anhydrous DCM and transfer the solution dropwise to the reaction mixture (for ~5 min).
12| Stir the reaction mixture under N 2 for 5 min. 19| Place a stopper on the separatory funnel and shake vigorously 10 times. Remove the stopper, transfer the organic layer to a 250-ml conical flask and discard the aqueous layer in another 250-ml container. Transfer the organic layer back to the separatory funnel and repeat the step after adding another 50 ml of dH 2 O. 27| Add a magnetic stir bar (cylindrical stirring bar 10 × 3 mm) to the microwave reaction vessel.
20|

28|
Place 198 mg of compound 3 (1.5 equiv., 0.44 mmol) in a 5-ml round-bottom flask and transfer the compound to the microwave reaction vessel with anhydrous DMF (1.2 ml in 100-µl portions) using a micropipette. Shake the resulting solution.
29| Using a micropipette, add 22 µl (0.29 mmol) of TFA to the microwave reaction vessel, and close the reaction vessel with a microwave cap. ! cautIon Because of the volatility and corrosiveness of TFA, we recommend using a glass syringe or pipette.
30|
Sonicate the solution for 10 s. . When a compound is detected, change to isocratic mode until the compound is completely eluted. For loading, dissolve the crude mixture in 15 ml of EtOAc in a round-bottom flask and add two spatula tips of silica to the resulting solution. Subsequently, remove the solvent under reduced pressure (water bath max. T: 40 °C) using a rotary evaporator. Transfer the silica-adsorbed crude mixture to a 60-ml polystyrene syringe cartridge and load into a CombiFlash purification system. Run the flash column chromatography with EtOAc/hexane at 30 ml min −1 and collect 12-ml fractions. Typically, compound 1 elutes when the EtOAc/hexane volume ratio is 3:7. When 40-g columns are used, the product elutes when the EtOAc/hexane volume ratio is 1:1. Compound 1 is isolated as a red amorphous solid. The solid can be analyzed by HPLC-MS to check the purity and exact mass (t R : 9.6 min; HPLC-MS (condition 1), table 2).  pause poInt Compound 1 can be safely stored for at least 4 months at 4 °C under N 2 . See Steps 36 and 37 for guidelines on how to test for purity after storage, and how to determine the shelf life of the compound.
(optional) analysis of samples of amino acid 1 stored for up to 4 months • tIMInG 1 h 36| If compound 1, as obtained after completing Step 35 above, is not used immediately after purification and is instead stored, its chemical purity must be reconfirmed before use. To test the compound stability as a solid, weigh 5 mg of amino acid 1 into a 2-ml glass vial and wrap in aluminum foil. To test the compound stability in solution, weigh 2.2 mg of amino acid 1 into a 50-ml centrifuge tube and dissolve it in 30 ml of DCM, MeOH or DMF to obtain a 0.1 M solution.
Divide the solution into aliquots in three separate 15-ml conical tubes (10 ml each) and wrap them in aluminum foil. into a 6-ml polystyrene syringe with a polyethylene porous disc. Place it in the vacuum manifold using a two-way stopcock.
37|
39| Swell the resin with DCM with gentle agitation using a Teflon stirring rod (2 × 4 ml × 15 s).
40|
Calculate the amount of the first amino acid (Fmoc-Gly-OH) to achieve a loading capacity ~1 mmol g −1 (i.e., mass of resin (g) × 1 mmol g −1 × amino acid molecular weight (g mol −1 ), see table 4).
41| Weigh 14 mg of Fmoc-Gly-OH in a 1.5-ml microcentrifuge tube. Add to the tube 0.5 ml of DCM and 24 µl of DIPEA. Shake for a few seconds until the solid dissolves completely and add the solution to the syringe, followed by manual stirring using a Teflon stirring rod. Wash the microcentrifuge tube with 0.5 ml of DCM and add the washing liquid to the syringe, followed by manual stirring using a Teflon stirring rod. 45| Put the syringe in the vacuum manifold and drain the resin.
42|
46|
Wash the resin thoroughly with DCM (4 × 3 ml × 10 s) and DMF (4 × 3 ml × 10 s), and apply vacuum to drain the resin after each wash.
47|
Add to the syringe a piperidine/DMF (1: 4) solution to remove the Fmoc-protecting group (1 × 5 ml × 1 min + 2 × 5 ml × 5 min). For each wash, gently stir the reaction mixture with the Teflon stirring rod and then drain the resin under vacuum.
48|
Calculate the amount of the second amino acid and the coupling reagents (Fmoc-Trp-OH, DIC and OxymaPure) needed on the basis of the amount of resin and functionalization (i.e., mass of resin (g) × 1 mmol g −1 × 3 equiv. × reagent molecular weight (g mol −1 ) see table 4).
49|
Weigh the amino acid and OxymaPure as calculated in Step 48 in a 1.5-ml microcentrifuge tube.
50|
Wash the resin thoroughly with DCM (4 × 3 ml × 10 s) and DMF (4 × 3 ml × 10 s), and apply a vacuum to drain the resin after each wash.  pause poInt Peptide elongation can be paused at any point after the incorporation of the third amino acid. Pausing after the incorporation of the second amino acid is not recommended because of the potential formation of diketopiperazines 54 . Storing the Fmoc-protected peptide is not recommended, because leftover traces of base can partially remove the Fmoc group and lead to the incorporation of a fluorenylmethyl group into the free amine. For storage, wash the resin 3 times with DCM or DMF (5 ml each), wrap the syringe in aluminum foil and store it at RT. The resin can be safely stored at 4 °C for at least 24 h.
56|
For the coupling of amino acid 1, calculate the amount of amino acid and coupling reagents (1, HOBt, PyBOP and DIPEA) needed on the basis of the amount of resin and functionalization (i.e., mass of resin (g) × 1 mmol g −1 × 1.5 or 2 equiv. × reagent molecular weight (g mol −1 ); see table 4).
57|
Weigh the amino acid and HOBt in a 1.5-ml microcentrifuge tube as calculated in Step 56. Weigh PyBOP in a separate 1.5-ml microcentrifuge tube.
58|
Wash the resin thoroughly with DCM (4 × 3 ml × 10 s) and DMF (4 × 3 ml × 10 s), and apply vacuum to drain the resin after each wash. 62| Run a Kaiser test 53 to assess the extent of the coupling.
? trouBlesHootInG  pause poInt For storage, wash and drain the resin three times with DCM (5 ml of DCM per wash-drain cycle), wrap the syringe in aluminum foil and store the resin at RT for 24 h.
63|
Wash the resin thoroughly with DCM (4 × 3 ml × 10 s) and DMF (4 × 3 ml × 10 s), and apply a vacuum to drain the resin after each wash. ! cautIon Always use a Teflon two-way stopcock when working with TFA (see next step). ! cautIon H 2 is a highly flammable gas. H 2 gas must be always handled inside a ventilated fume hood. ! cautIon Once the reaction is complete and before the workup, the H 2 atmosphere should be replaced by N 2 or Ar before filtering in order to avoid ignition of the charcoal. 103| Transfer samples to a 96-well polystyrene transparent plate using a multichannel pipette. As a reference for background measurements, make sure to fill three wells with 150 µl of DPBS each.
64|
104|
Measure absorbance spectra of the 96-well transparent plate using a Synergy H1 spectrophotometer. Absorbance range is 420-550 nm (every 1 nm).
105|
Transfer BODIPY-cPAF26 suspensions with high liposome content, those with low liposome content, the DPBS blank and fluorescein in basic EtOH to 2-ml glass vials.
106|
Irradiate the glass vials with 365-nm light using a hand-held UV lamp. Differences in fluorescence intensity of BODIPY-cPAF26 can be detected by the naked eye (Fig. 12) . ! cautIon Exposure to UV radiation can cause skin or eye burns; hence, protective equipment (goggles, gloves and lab coat) should be worn.
? trouBlesHootInG testing of BoDIpY-cpaF26 cytotoxicity in a549 human lung epithelial cells • tIMInG 42 h  crItIcal Cell culture experiments must be performed in sterile conditions using a class II microbiological safety cabinet. All reagents (media, DPBS, trypsin-EDTA) and pipette tips must be sterile. 107| Use a running culture of A549 cells, typically one T-75 cell culture flask with 25 ml of cell culture medium (see Reagent Setup) incubated at 37 °C in 5% CO 2 .
108| Check confluency and morphology of the cells under a microscope.  crItIcal step Live A549 cells should adhere to the flask. If most cells are floating or show signs of contamination (e.g., the presence of bacteria or a cloudy medium), discard the culture and use a new batch.
109|
Remove and discard the medium with a 25-ml plastic pipette.
110|
Gently add 10 ml of Ca 2+ -free DPBS to wash the cells, and then remove and discard the washing liquid with a 10-ml plastic pipette.
111| Add 1 ml of trypsin-EDTA to the flask, rock gently to cover the entire surface of the flask and incubate for 3 min at 37 °C in 5% CO 2 .
? trouBlesHootInG 112| Remove the flask from the incubator, tap gently to detach cells, add 10 ml of cell culture medium to the flask and transfer the cell suspension to a 50-ml centrifuge tube.
113| Collect a 50-µl aliquot of the cell suspension for cell counting.
114| Determine the number of cells using a cell counter. In one fully confluent flask of A549 cells, counts are typically ~0.5-2 × 10 6 cells ml −1 , depending on their manipulation. 116| Discard the supernatant and resuspend the cell pellet in 1 ml of cell culture medium. Calculate the amount of cells needed for the cytotoxicity assay, depending on the number of wells to be used (25,000 cells per well). In a standard assay with six different conditions and four replicates (total of 24 wells), ~6 × 10 5 cells are needed.
117| Dilute the cell suspension in cell culture medium to achieve a final concentration of 2.5 × 10 5 cells ml −1 , and place the cell suspension in a 50-ml pipette basin.
118|
Using a multichannel pipette, plate cells (100 µl per well) in sterile 96-well flat-bottom polystyrene clear plates with lids. Discard leftover cells, following the relevant biological waste disposal regulations.
119|
Incubate the plate(s) for 16 h at 37 °C in 5% CO 2 .
120| Check the confluency and morphology of the cells under a microscope.
? trouBlesHootInG 121| Transfer 4 µl of a 5 mM BODIPY-cPAF26 solution to a 1.5-ml microcentrifuge tube and add 16 µl of DMSO to prepare a 1 mM solution.
122|
Prepare three more dilutions from 1 mM BODIPY-cPAF26 in DMSO (2-fold serial dilutions) in separate 1.5-ml microcentrifuge tubes to obtain 0.5, 0.25 and 0.125 mM DMSO solutions. 126| Dilute an appropriate volume of MTT reagent with cell culture medium (2.3-fold dilution, a minimum of 30 µl solution per well is required), and place the solution in a 50-ml pipette basin.
123|
127|
Using a multichannel pipette, add 30 µl of the MTT in cell culture medium solution just prepared to each well.
128|
Rock the plate(s) gently and incubate the cells for 4 h at 37 °C in 5% CO 2 .  crItIcal step Under the microscope, check the progression of the MTT reaction by observing the precipitation of a dark solid within the cells. ? trouBlesHootInG 129| Place enough detergent reagent in a 50-ml pipette basin (a minimum of 100 µl of detergent per well is required).
130|
Using a multichannel pipette, add 100 µl of detergent to each well. Rock the plate gently, wrap it in aluminum foil and keep it at RT for a minimum of 2 h.  crItIcal step Typically, 2-4 h of incubation with detergent is long enough to obtain the needed data, but overnight incubation is recommended to ensure full solubilization of the MTT reagent.  pause poInt At this point, the experiment can be paused and the plate can be kept at RT overnight.
131| Measure absorbance at 570 nm and 650 nm (background signal) of the 96-well transparent plate using a Synergy H1 spectrophotometer. Wells with high cell viability values (DPBS-containing negative control) are dark colored, whereas wells with low cell viability (full DMSO positive control) are yellow colored (Fig. 13) . Absorbance values should be between 0.5 and 1.5 absorbance units (AU 
146|
Filter the cell suspension through folded Miracloth (4 layers) and transfer it to a sterile 50-ml centrifuge tube.
147|
Centrifuge the suspension for 10 min at RT (4,000 r.p.m., 1,755g) and discard the supernatant.
148|
Resuspend the pellet in 2 ml of sterile dH 2 O and, using a P1000 micropipette, transfer the resulting suspension to a 2-ml microcentrifuge tube.
149| Remove a 4-µl aliquot of the cell suspension and transfer it to a hemocytometer to count the spores.  crItIcal step Past the 1-month storage mark, F. oxysporum conidia must be discarded following relevant biological waste disposal regulations. All inoculations should be performed from original stock cultures and not from subcultures, in order to reduce the possibility of cultures acquiring new mutations.  pause poInt F. oxysporum conidia suspension in sterile dH 2 O can be stored for up to 1 month at 4 °C. 154| Add 100 µl of the 30 µM peptide solution to each of the wells in the first column (A1-G1) of a transparent U-bottom 96-well plate (Fig. 14a) .
155| Add 100 µl of the 25 µM peptide solution to each of the wells in the second column (A2-G2) of a transparent U-bottom 96-well plate (Fig. 14a) .
156| Add 100 µl of sterile dH 2 O to each of wells D1, H1, D2 and H2, and 50 µl of sterile dH 2 O to each of the rest of the wells.
157|
Using a multichannel electronic pipette, perform 2-fold serial dilutions of the 30 µM peptide solution prepared in
Step 153 by transferring 50 µl from column 1 to column 3 and then transfer 50 µl from column 3 to column 5 and so on. Discard the 50 µl taken from column 11 (Fig. 14b) .
158| Using a multichannel electronic pipette, perform 2-fold serial dilutions of the 25 µM peptide solution prepared in
Step 153 by transferring 50 µl from column 2 to column 4 and then transfer 50 µl from column 4 to column 6 and so on. Discard the 50 µl taken from column 10 (Fig. 14c) . 160| Using a multichannel pipette, add 50 µl of the conidial suspension just obtained to each well to achieve a final volume of 100 µl/well and a concentration of 5 × 10 5 cells ml −1 , excluding wells that will act as blanks in rows D and H. To the blank wells in rows D and H, add 50 µl of a solution of liquid Vogel's sucrose minimal medium in dH 2 O (1:4) to achieve a final volume of 100 µl per well (Fig. 14d) .  crItIcal step The addition of the conidia to the wells of the 96-well plate must be performed quickly to avoid any of the conidia settling in the pipette basin.
161| Put the lid on the plate and wrap it in aluminum foil. Incubate for 24 h at 37 °C in the case of A. fumigatus or at 25 °C in the case of N. crassa.
162|
Measure the OD of the contents of the plate at 610 nm using a spectrophotometer. OD values for the control group (conidia alone) should be ~0.1-0.2 AU. IC 50 values are determined by four-parameter logistic regression analysis.
? trouBlesHootInG 
